Matches in Wikidata for { <http://www.wikidata.org/entity/Q64622930> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q64622930 description "clinical trial" @default.
- Q64622930 description "ensayu clínicu" @default.
- Q64622930 description "klinisch onderzoek" @default.
- Q64622930 description "клінічне випробування" @default.
- Q64622930 name "OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)" @default.
- Q64622930 type Item @default.
- Q64622930 label "OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)" @default.
- Q64622930 prefLabel "OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)" @default.
- Q64622930 P1050 Q64622930-DB02998F-C0E1-428D-9364-72A8884CDB15 @default.
- Q64622930 P1132 Q64622930-AB7BC275-8529-4424-9D0D-69A6D0EDD426 @default.
- Q64622930 P1476 Q64622930-EB39D4FB-0E71-4D24-9E59-A97E04965D1A @default.
- Q64622930 P17 Q64622930-0C0CE6F7-1BCF-42CD-B959-44254A3C0543 @default.
- Q64622930 P17 Q64622930-91A8D730-7208-4D60-AD7C-536D0F9B7A8B @default.
- Q64622930 P1813 Q64622930-FB54E33D-9DBA-4EB3-9D0A-D1619973D4A4 @default.
- Q64622930 P2899 Q64622930-31C668D4-C10B-48A0-9E2F-793A1151DAAC @default.
- Q64622930 P3098 Q64622930-560335F7-6067-4838-82D6-C39A79D20C44 @default.
- Q64622930 P31 Q64622930-7FE6A19A-6030-49CA-A49E-B3E95CFA27A1 @default.
- Q64622930 P4844 Q64622930-FE7A3D4A-B092-4750-BF5C-25EE38CDC95A @default.
- Q64622930 P580 Q64622930-D3598747-24DE-49F8-806B-5583083B620E @default.
- Q64622930 P582 Q64622930-7E5A86F9-72D8-4631-A570-1146640D8711 @default.
- Q64622930 P6099 Q64622930-DD21E594-B441-46AA-8A76-17A961CA679D @default.
- Q64622930 P6153 Q64622930-015421B9-6190-4E21-A6AF-F2D5E9194C84 @default.
- Q64622930 P6153 Q64622930-84500442-AAAC-4688-8B84-236FFB6EE35F @default.
- Q64622930 P6153 Q64622930-DB9C9DD9-A42E-4DEC-9E3E-2214443EF5D4 @default.
- Q64622930 P6153 Q64622930-EC8023E3-477E-4B7A-894D-BBE187B271C1 @default.
- Q64622930 P8363 Q64622930-43D2FA7B-FDB7-44BE-838D-A3FD65677743 @default.
- Q64622930 P1050 Q29496 @default.
- Q64622930 P1132 "+289" @default.
- Q64622930 P1476 "A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATING THE OPTIMIZATION OF THE RESIDUAL PLASMATIC LEVEL OF DASATINIB (SPRYCEL®) IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML)." @default.
- Q64622930 P17 Q142 @default.
- Q64622930 P17 Q16 @default.
- Q64622930 P1813 "OPTIM-DASA" @default.
- Q64622930 P2899 "+18" @default.
- Q64622930 P3098 "NCT01916785" @default.
- Q64622930 P31 Q30612 @default.
- Q64622930 P4844 Q419940 @default.
- Q64622930 P580 "2009-05-01T00:00:00Z" @default.
- Q64622930 P582 "2013-12-01T00:00:00Z" @default.
- Q64622930 P6099 Q42824440 @default.
- Q64622930 P6153 Q2945751 @default.
- Q64622930 P6153 Q2945753 @default.
- Q64622930 P6153 Q2945769 @default.
- Q64622930 P6153 Q3151784 @default.
- Q64622930 P8363 Q78089383 @default.